Filed by Zymeworks Delaware Inc.
Pursuant to Rule 425 under the Securities Act of 1933
and deemed filed pursuant to Rule 14a-12
under the Securities Exchange Act of 1934
Subject Company: Zymeworks Inc.
Commission File No. for Registration Statement on Form S-4
filed by Zymeworks Delaware Inc.: 333-266160
On July 15, 2022, Zymeworks Inc. made available
to investors and the public a pre-recorded webcast presentation. The transcript of the presentation is included below, and the slides used in the presentation are being separately filed pursuant to Rule 425.
Operator:
(Slide 1)
Thank you for standing by, this is the conference operator.
Welcome to Zymeworks Delaware Redomicile Webcast. As a reminder, all participants are in listen-only mode and the webcast is being
recorded.
I would now like to turn the conference over to Jack Spinks, Head of Investor Relations at Zymeworks. Jack, please go
ahead.
Slide 2
Jack Spinks:
Good morning and welcome everyone. Thank you for joining. My name is Jack Spinks, Associate Director of Investor Relations here at
Zymeworks. Before I turn the call over to Neil Klompas, our Chief Operating Officer, who will speak to you today about this mornings announcement of Zymeworks plan to become a Delaware domiciled company, I would like to first
briefly remind you that during todays call we will be making forward-looking statements. Forward-looking statements can be identified by words such as should, would,
will, continue, may, potential, initiate, look forward to, expect, believe, plan, anticipate,
enable and similar words. Forward-looking statements are based upon our current expectations and various assumptions and are subject to the usual risks and uncertainties associated with companies in our industry and at our
stage of development. In this webcast, forward-looking statements will also include statements about the anticipated benefits of the proposed redomicile, the anticipated timing to complete the redomicile, anticipated tax impacts to Zymeworks and its
shareholders, the impact of the proposed redomicile on Zymeworks ability to achieve its strategic objectives, anticipated operational expansion in Asia and the EU, and statements about the anticipated development of our business and
accomplishment of our strategic priorities. For detailed information about the risks and uncertainties faced by Zymeworks, please refer to the Risk Factors section in the registration statement on Form
S-4 to be filed by Zymeworks Delaware Inc. with the SEC and on SEDAR, as well as our other SEC filings as found on our website at www..zymeworks.com and as filed with the SEC.